NCT02939807 - A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter

Timeline

Start Date

September 30, 2019

Primary Completion Date

September 30, 2023

Study Completion Date

January 30, 2024

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

ABC294640

"ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.~ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days."

Trial Locations (1)

29425

Medical University of South Carolina, Charleston